Bourlon CRE, López NM

Language: Spanish
References: 20
Page: 590-596
PDF size: 696.10 Kb.

ABSTRACT

Atherosclerosis is associated with 75% of deaths from cardiovascular disease. The absence of modifications possible risk factors leading to the development and worsening of the disease. The pathogenesis begins with the accumulation of fats high in cholesterol and chronic inflammatory response in susceptible sites of blood vessel walls. Natural history of atherosclerosis depends on whether or not spontaneous regression of lesions in the early stages, the plate can remain stable and is asymptomatic. Imaging studies are a useful tool for early detection of atherosclerosis in high risk patients for evaluation in those who have suffered a cardiovascular clinical event that can be benefited with the change or initiation of secondary prevention therapy.

REFERENCES

1. Insull W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med 2009;122(Suppl 1):S3-S14.

2. Lewis S. Prevention and treatment of atherosclerosis: a practitioner´s guide for 2008. Am J Med 2009;122(1A):S38-S50.

3. Dod H, Bhardwaj R, Sajja V, et al. Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. Am J Cardiol 2010;105:362-367.

4. Razani B, Chakravarthy MV, Semenkovich CF. Insuline resistance and atherosclerosis. Endocrinol Metab Clin N Am.2008;37:603-621.

5. Kalva SP, Mueller PR. Vascular Imaging in the elderly. Radiol Clin N Am 2008;46:663-683.

6. http://www.mdconsult.com/book/player/book: Libby: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th Edition, Part VI, Chapter 38: The Vascular Biology of Atherosclerosis.

7. Suzuki T, Hirata K, et al. Metabolic syndrome, endothelial dysfunction and risk of cardiovascular events: The Northern Manhattan Study (NOMAS). Am Heart J 2008;156:405-410.

8. Cannon CP. Mixed dyslipidemia, metabolic syndrome, diabetes mellitus and cardiovascular disease: Clinical implications. Am J Card 2008;102(suppl):5L-9L.

9. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of metabolic syndrome An American Heart Association/ National Heart, Lung, and Blood Institute. Circulation 2005; 112:e285-e290.

10. Levesque J, Lamarche B. The metabolic syndrome: Definitions, prevalence and management. J Nutrigenet Nutrigenomics 2008;1:100-108.

11. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insuline resistance. Clinical Cornerstone 2006;8(Suppl 1):S21-17.

12. Gans RO. The metabolic syndrome, depression and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin N Am 2006;90:573-591.

13. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: incidence, prevalence, mortality and risk factors. Neurol Clin 2008;26:871-895.

14. Bang OY. Adiponectin levels in patients with intracranial atherosclerosis. Neurology 2007; 69(22):1931-1937.

15. Bansilal S, Farkouh M, Fuster V. Role of Insulin Resistance and Hyperglycemia in the Development of Atherosclerosis. Am J Cardiol 2007;99(Supp1):6B-14B.

16. García BD, García RF, García JP, et al. Diagnóstico preclínico de la aterosclerosis: función endotelial. Rev Cubana Med 2003;42(1):58-63.

17. Kathiresan S, Larson MG, et al. Assesment by Cardiovascular Magnetic Resonance, electron Bean Computed Tomography and Carotid Ultrasonography of the distribution of subclinical atherosclerosis across Framingham Risk Strata. Am J Cardiol 2007;99(3):310-314.

18. Feldmann E, Kosinski A, Lynn M, et al. The Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA) Trial. Neurology 2007;68:2099-2106.

19. Feinstein SB. Diabetes Mellitus and Noninvasive Imaging of Atherosclerosis. Am J Cardiol 2007;99(Suppl):89B-95B.

20. Ibañez B, Badimon, García M. Diagnosis of Atherosclerosis by Imaging. Am J Med 2009;122:S15-S25.